Concentration of Risk

Moderna, Inc.

Medium

MRNA · Nasdaq · Biological Products, (No Diagnostic Substances) · CIK 0001682852

Latest filing: 10-K · 2026-02-20

Customer concentration

Significant Customers note · revenue dependency

Medium
Top exposure
15%
FFF Enterprises
Other major customers
Public Works and Government Services Canada13%
Cardinal Health11%
Each is a separate customer disclosed individually — the figures are not sub-parts of the headline and may be measured against different revenue bases, so they are not additive.
+2.0pp YoY

Click a point to open the SEC source

FY24FY250%4%8%12%16%

Geographic concentration

Segment reporting · geographic revenue

High
Top exposure
61.7%
United States
Flat

Click a point to open the SEC source

FY250%20%40%60%80%

Supplier concentration

Risk Factors · supply chain dependency

Low
Dependency
Single source
Single sourceNamed
Qualitative disclosure — no % quantified (informational, not scored)
Flat
FY25

Qualitative dependency level by filing year.

Product concentration

ASC 275 · disclosed dependence on a specific product or service

Low
Top exposure
<10%
No disclosure detected
Flat

Credit concentration

ASC 825 · concentration of credit risk note

Medium
Receivables
33%
Public Works and Government Services Canada
Flat

Click a point to open the SEC source

FY250%9%18%27%36%